Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping ...

Fresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations for its lead immuno-oncology drug. The Irish-American biotech picked up the ...

PARAMUS, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...